Xencor (NASDAQ:XNCR) Reaches New 52-Week Low – Time to Sell?

Xencor, Inc. (NASDAQ:XNCR) reached a new 52-week low during trading on Monday . The company traded as low as $8.15 and last traded at $8.48, with a volume of 78303 shares. The stock had previously closed at $8.69.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Price Performance

The stock’s 50-day moving average is $13.84 and its 200 day moving average is $19.41. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market cap of $620.77 million, a PE ratio of -2.75 and a beta of 0.90.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. On average, equities analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC boosted its holdings in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Xencor during the 4th quarter worth about $34,000. GAMMA Investing LLC grew its position in shares of Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares during the period. KBC Group NV increased its stake in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in Xencor by 49.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 1,337 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.